Robert Haddad, MD
Enriched profileChief, Division of Head and Neck Oncology · Dana-Farber Cancer Institute
Robert Haddad is Chief, Division of Head and Neck Oncology at Dana-Farber Cancer Institute. ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 13 Nov 2026
Overview
Updated 17 Nov 2026
Robert Haddad, MD, is Chief, Division of Head and Neck Oncology at Dana-Farber Cancer Institute. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2019–2019).
- Top research focus: Head & Neck Cancer
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Nov 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 13 Nov 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202545 payments$56,081openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year20257 payments$10,120openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20257 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Antiarrhythmic100%Lidocaine Hcl Viscous100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Nov 2026
1 NIH research award on record, funded 2019–2019 per NIH RePORTER. The latest:
- Defining mechanisms of immunotherapy resistance in head and neck squamous cell carcinomas
Dana-Farber Cancer Inst
FY2019$4,259,203U01DE029188
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 13 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-haddad-md-bc5537b3
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
dana-farber.org/find-a-doctor/robert-i-haddad
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Other
hcc.harvard.edu/members/dr-robert-haddad
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcc.harvard.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD Degree
St. Joseph University French School of Medicine in Beirut
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗ - Member
American Association for Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗ - Member
European Society of Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗ - Member
American Society for Therapeutic Radiology and Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connects.catalyst.harvard.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Harvard Medical School
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗ - McGraw Chair in Head and Neck Oncology
Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerhealth.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Frank Hodi, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington